These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22246524)

  • 1. N-acetyltransferase-2 gene polymorphisms and prostate cancer susceptibility in Latin American patients.
    de Lima Junior MM; Reis LO; Guilhen AC; Granja F; de Lima Oliveira MN; Ferreira U; Cunha LL; Ward LS
    Med Oncol; 2012 Dec; 29(4):2889-94. PubMed ID: 22246524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men.
    Hamasaki T; Inatomi H; Katoh T; Aono H; Ikuyama T; Muratani T; Matsumoto T
    Int J Urol; 2003 Mar; 10(3):167-73. PubMed ID: 12622714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study.
    Wang CY; Jones RF; Debiec-Rychter M; Soos G; Haas GP
    Anticancer Res; 2002; 22(6B):3529-35. PubMed ID: 12552951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population.
    Kiyohara C; Washio M; Horiuchi T; Tada Y; Asami T; Ide S; Takahashi H; Kobashi G;
    Lupus; 2009 Jun; 18(7):630-8. PubMed ID: 19433464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in N-acetyltransferase 2 (NAT2), smoking and risk of prostate cancer in the Slovak population.
    Vilčková M; Jurečeková J; Dobrota D; Habalová V; Klimčáková L; Waczulíková I; Slezák P; Kliment J; Sivoňová MK
    Med Oncol; 2014 Jun; 31(6):987. PubMed ID: 24816842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study.
    Hein DW; Leff MA; Ishibe N; Sinha R; Frazier HA; Doll MA; Xiao GH; Weinrich MC; Caporaso NE
    Environ Mol Mutagen; 2002; 40(3):161-7. PubMed ID: 12355549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population.
    Costa S; Pinto D; Morais A; Vasconcelos A; Oliveira J; Lopes C; Medeiros R
    Prostate; 2005 Aug; 64(3):246-52. PubMed ID: 15717312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
    Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
    J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma.
    Prawan A; Kukongviriyapan V; Tassaneeyakul W; Pairojkul C; Bhudhisawasdi V
    Eur J Cancer Prev; 2005 Jun; 14(3):245-50. PubMed ID: 15901993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk.
    Bouchardy C; Mitrunen K; Wikman H; Husgafvel-Pursiainen K; Dayer P; Benhamou S; Hirvonen A
    Pharmacogenetics; 1998 Aug; 8(4):291-8. PubMed ID: 9731715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility.
    Wikman H; Thiel S; Jäger B; Schmezer P; Spiegelhalder B; Edler L; Dienemann H; Kayser K; Schulz V; Drings P; Bartsch H; Risch A
    Pharmacogenetics; 2001 Mar; 11(2):157-68. PubMed ID: 11266080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
    Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
    Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese.
    Inatomi H; Katoh T; Kawamoto T; Matsumoto T
    Int J Urol; 1999 Sep; 6(9):446-54. PubMed ID: 10510890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population.
    Srivastava DS; Mittal RD
    BMC Urol; 2005 Aug; 5():12. PubMed ID: 16083506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer.
    Alberg AJ; Daudt A; Huang HY; Hoffman SC; Comstock GW; Helzlsouer KJ; Strickland PT; Bell DA
    Cancer Detect Prev; 2004; 28(3):187-93. PubMed ID: 15225898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
    Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
    Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer.
    da Silva TD; Felipe AV; de Lima JM; Oshima CT; Forones NM
    World J Gastroenterol; 2011 Feb; 17(6):760-5. PubMed ID: 21390146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
    Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
    DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.